CRISPR gene editing holds immense promise for curing genetic diseases, but I worry we're moving too fast without fully understanding long-term effects. Off-target mutations and mosaicism are real risks that our current safety assessments may miss. Should we slow down clinical applications until we have better predictive models, or is the urgency to help patients worth the uncertainty?